-
公开(公告)号：US20210324094A1
公开(公告)日：2021-10-21
申请号：US17285367
申请日：2019-10-18
Applicant: MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH
Inventor： Ki Joon CHO , Mijung LEE , Eun Jung SONG , Ki Su KIM , Kwan Yub KANG , Eui Cheol CHO
Abstract: An asymmetric fusion protein in which a fragment of an antibody binding to an insulin receptor, an iduronate-2-sulfatase (IDS) enzyme, and an Fc region are fused, and a use thereof are disclosed. The fusion protein can cross the blood-brain barrier (BBB) to deliver the IDS enzyme to the brain. Therefore, a pharmaceutical composition containing the fusion protein as an active ingredient can be used as a therapeutic agent for a central nervous system disease and particularly, is expected to prevent and treat various diseases caused by ribosome accumulation.
-
公开(公告)号：US20180030151A1
公开(公告)日：2018-02-01
申请号：US15553292
申请日：2015-12-29
Applicant: MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH
Inventor： Dong-Sik KIM , Mi Jung LEE , Jae Chan PARK , Sumin LEE , Heechun KWAK , SungHo HWANG , Hyung-Kwon LIM , Kisu KIM , Young Seoub PARK , Junhong JEONG , Ki Joon CHO
IPC: C07K16/38
CPC classification number: C07K16/38 , C07K2317/24 , C07K2317/34 , C07K2317/565 , C07K2317/622 , C07K2317/72 , C07K2317/92
Abstract: The present invention relates to an antibody that binds specifically to a tissue factor pathway inhibitor (TFPI), a nucleic acid encoding the antibody, a vector comprising the nucleic acid, a host cell transformed with the vector, a method for producing the antibody, and a pharmaceutical composition for treating hemophilia, which comprises the antibody as an active ingredient. The antibody of the present invention, which binds specifically to TFPI, can activate the extrinsic pathway of blood coagulation by inhibiting TFPI. Thus, the antibody of the present invention can be effectively used for the treatment of antibody-induced hemophilia patients and for the prevention of blood coagulation disease in hemophilia-A or hemophilia-B patients.
-
Search Results
2
records
(took 0.016 seconds)
